Eli Lilly and Company (NYSE:LLY) Shares Purchased by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 3.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,150 shares of the company’s stock after purchasing an additional 35 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Eli Lilly and Company were worth $670,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Russell Investments Group Ltd. grew its stake in shares of Eli Lilly and Company by 1.6% in the fourth quarter. Russell Investments Group Ltd. now owns 516,804 shares of the company’s stock worth $301,107,000 after purchasing an additional 8,309 shares in the last quarter. Private Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 31.9% in the fourth quarter. Private Wealth Partners LLC now owns 4,730 shares of the company’s stock worth $2,757,000 after purchasing an additional 1,145 shares in the last quarter. Valmark Advisers Inc. grew its stake in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Valmark Advisers Inc. now owns 4,543 shares of the company’s stock worth $2,648,000 after purchasing an additional 69 shares in the last quarter. Gilliland Jeter Wealth Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $673,000. Finally, Terril Brothers Inc. grew its stake in shares of Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after purchasing an additional 429 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 1.2 %

Eli Lilly and Company stock traded up $8.64 during mid-day trading on Friday, hitting $733.51. The company’s stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The firm’s 50 day moving average is $761.79 and its 200 day moving average is $666.06. The company has a market cap of $696.95 billion, a PE ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 52-week low of $380.77 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.09 EPS. On average, analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LLY shares. Wells Fargo & Company increased their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. BMO Capital Markets raised their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Barclays raised their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.